NASDAQ:MDGL

Madrigal Pharmaceuticals Competitors

$124.77
-1.88 (-1.48 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$121.94
Now: $124.77
$128.00
50-Day Range
$112.08
MA: $117.27
$123.06
52-Week Range
$74.20
Now: $124.77
$137.28
Volume132,412 shs
Average Volume181,014 shs
Market Capitalization$2.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.19

Competitors

Madrigal Pharmaceuticals (NASDAQ:MDGL) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying MDGL stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Madrigal Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Volatility and Risk

Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Madrigal Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Madrigal PharmaceuticalsN/A-47.64%-43.21%
Amgen29.42%95.55%15.52%

Insider & Institutional Ownership

74.2% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 0.4% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Madrigal Pharmaceuticals and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Madrigal Pharmaceuticals03702.70
Amgen091402.61

Madrigal Pharmaceuticals currently has a consensus price target of $167.60, indicating a potential upside of 34.33%. Amgen has a consensus price target of $261.0476, indicating a potential upside of 1.67%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Madrigal Pharmaceuticals is more favorable than Amgen.

Earnings & Valuation

This table compares Madrigal Pharmaceuticals and Amgen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-22.89
Amgen$23.36 billion6.33$7.84 billion$14.8217.33

Amgen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Madrigal Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Profitability

This table compares Madrigal Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Madrigal PharmaceuticalsN/A-47.64%-43.21%
Gilead Sciences5.48%37.77%12.76%

Institutional & Insider Ownership

74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Madrigal Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Madrigal Pharmaceuticals03702.70
Gilead Sciences191302.52

Madrigal Pharmaceuticals presently has a consensus price target of $167.60, indicating a potential upside of 34.33%. Gilead Sciences has a consensus price target of $97.92, indicating a potential upside of 46.43%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Madrigal Pharmaceuticals.

Earnings and Valuation

This table compares Madrigal Pharmaceuticals and Gilead Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-22.89
Gilead Sciences$22.45 billion3.75$5.39 billion$6.1410.89

Gilead Sciences has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Madrigal Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Institutional & Insider Ownership

74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Madrigal Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Madrigal Pharmaceuticals03702.70
Vertex Pharmaceuticals042112.88

Madrigal Pharmaceuticals presently has a consensus price target of $167.60, indicating a potential upside of 34.33%. Vertex Pharmaceuticals has a consensus price target of $293.1250, indicating a potential upside of 32.98%. Given Madrigal Pharmaceuticals' higher probable upside, research analysts clearly believe Madrigal Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares Madrigal Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Madrigal PharmaceuticalsN/A-47.64%-43.21%
Vertex Pharmaceuticals38.51%28.55%20.68%

Earnings and Valuation

This table compares Madrigal Pharmaceuticals and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-22.89
Vertex Pharmaceuticals$4.16 billion13.64$1.18 billion$4.2951.14

Vertex Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Madrigal Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Regeneron Pharmaceuticals and Madrigal Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Madrigal Pharmaceuticals03702.70

Regeneron Pharmaceuticals presently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Madrigal Pharmaceuticals has a consensus price target of $167.60, suggesting a potential upside of 34.33%. Given Madrigal Pharmaceuticals' higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 41.9% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Madrigal Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-22.89

Regeneron Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Madrigal Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Madrigal PharmaceuticalsN/A-47.64%-43.21%

Summary

Regeneron Pharmaceuticals beats Madrigal Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Volatility and Risk

Madrigal Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Madrigal Pharmaceuticals and Biogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Madrigal Pharmaceuticals03702.70
Biogen5141202.23

Madrigal Pharmaceuticals currently has a consensus target price of $167.60, suggesting a potential upside of 34.33%. Biogen has a consensus target price of $303.5862, suggesting a potential upside of 12.12%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Madrigal Pharmaceuticals is more favorable than Biogen.

Earnings and Valuation

This table compares Madrigal Pharmaceuticals and Biogen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-22.89
Biogen$14.38 billion2.86$5.89 billion$33.578.05

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Madrigal Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Madrigal PharmaceuticalsN/A-47.64%-43.21%
Biogen35.63%51.00%23.54%

Summary

Biogen beats Madrigal Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Valuation and Earnings

This table compares Madrigal Pharmaceuticals and Alexion Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-22.89
Alexion Pharmaceuticals$4.99 billion7.21$2.40 billion$9.7416.80

Alexion Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

74.2% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Madrigal Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Madrigal Pharmaceuticals03702.70
Alexion Pharmaceuticals017512.30

Madrigal Pharmaceuticals currently has a consensus target price of $167.60, suggesting a potential upside of 34.33%. Alexion Pharmaceuticals has a consensus target price of $153.8636, suggesting a potential downside of 6.00%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Madrigal Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Madrigal PharmaceuticalsN/A-47.64%-43.21%
Alexion Pharmaceuticals16.32%23.16%14.76%

Summary

Alexion Pharmaceuticals beats Madrigal Pharmaceuticals on 10 of the 14 factors compared between the two stocks.


Madrigal Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$256.76-0.6%$146.90 billion$23.36 billion20.71Insider Selling
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.87-1.6%$84.19 billion$22.45 billion68.94Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$219.39-0.8%$56.78 billion$4.16 billion27.70
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.60-1.6%$53.84 billion$7.86 billion18.37Analyst Report
Biogen logo
BIIB
Biogen
1.9$270.31-0.0%$41.18 billion$14.38 billion8.95Upcoming Earnings
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$163.68-3.8%$35.98 billion$4.99 billion38.24Unusual Options Activity
News Coverage
Gap Down
Seagen logo
SGEN
Seagen
1.7$145.50-2.8%$26.38 billion$916.71 million57.28Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$130.04-0.4%$21.99 billion$876.29 million-58.84
Incyte logo
INCY
Incyte
1.7$82.68-0.6%$18.18 billion$2.16 billion-52.66
Novavax logo
NVAX
Novavax
1.2$227.35-11.1%$16.79 billion$18.66 million-43.55
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.29-0.5%$16.31 billion$219.75 million-17.66
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$78.92-0.2%$14.32 billion$1.70 billion18.06
Repligen logo
RGEN
Repligen
1.5$212.68-0.4%$11.70 billion$270.24 million259.37
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.58-1.6%$9.13 billion$788.10 million103.85Analyst Upgrade
Increase in Short Interest
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.85-1.1%$8.98 billion$1.45 billion19.29Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$23.59-1.5%$7.36 billion$967.78 million49.15
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.22-0.0%$6.62 billion$195.99 million288.88Insider Selling
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.31-5.3%$2.05 billion$638.60 million-10.50
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13
Codexis logo
CDXS
Codexis
1.3$23.60-4.0%$1.52 billion$68.46 million-67.43Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02
Innoviva logo
INVA
Innoviva
1.4$11.64-2.1%$1.21 billion$261.02 million5.94
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
MannKind logo
MNKD
MannKind
1.4$4.23-1.7%$1.07 billion$63.04 million-20.14Increase in Short Interest
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.90-1.4%$933.33 million$3.57 million-10.72Analyst Upgrade
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.36-8.8%$812.29 millionN/A0.00Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.96-5.0%$752.08 million$322.07 million-4.72Decrease in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33-2.7%$716.63 million$150,000.00-4.76
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.28-1.3%$669.56 million$252 million-2.07
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.98-2.0%$625.09 million$143.01 million-1.14
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58-5.6%$609.03 million$59.29 million-23.87Increase in Short Interest
Agenus logo
AGEN
Agenus
1.6$2.62-1.5%$536.28 million$150.05 million-2.40
Geron logo
GERN
Geron
1.4$1.47-2.7%$468.24 million$460,000.00-4.20Decrease in Short Interest
Verastem logo
VSTM
Verastem
1.3$2.68-0.4%$461.78 million$17.46 million-1.90
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.00-0.7%$461.18 million$109.33 million-2.21
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.12-7.3%$455.14 million$22.27 million-3.98Analyst Report
Insider Buying
Analyst Revision
XOMA logo
XOMA
XOMA
1.3$37.06-2.1%$426.12 million$18.37 million-33.39Increase in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.14-7.2%$421.39 million$36.63 million-4.87Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.